Institutional shares held 146 Million
68.8K calls
42.5K puts
Total value of holdings $992M
$468K calls
$289K puts
Market Cap $973M
142,872,992 Shares Out.
Institutional ownership 101.98%
# of Institutions 204


Latest Institutional Activity in ADPT

Top Purchases

Q4 2024
Gamma Investing LLC Shares Held: 9.81K ($66.8K)
Q4 2024
Sg Americas Securities, LLC Shares Held: 45.9K ($313K)
Q4 2024
Skopos Labs, Inc. Shares Held: 2.99K ($20.4K)
Q4 2024
Versant Capital Management, Inc Shares Held: 332 ($2.26K)
Q4 2024
Nisa Investment Advisors, LLC Shares Held: 13.1K ($89.4K)

Top Sells

Q4 2024
Bouvel Investment Partners, LLC Shares Held: 43.8K ($298K)
Q3 2024
Matrix Capital Management Company, LP Shares Held: 650K ($4.43M)
Q3 2024
Massachusetts Financial Services CO Shares Held: 2.88M ($19.6M)
Q3 2024
Soleus Capital Management, L.P. Shares Held: 1.11M ($7.58M)
Q3 2024
Jane Street Group, LLC Shares Held: 504K ($3.43M)

About ADPT

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.


Insider Transactions at ADPT

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
1.69M Shares
From 16 Insiders
Grant, award, or other acquisition 1.67M shares
Exercise of conversion of derivative security 20K shares
Sell / Disposition
209K Shares
From 8 Insiders
Open market or private sale 209K shares

Track Institutional and Insider Activities on ADPT

Follow Adaptive Biotechnologies Corp and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ADPT shares.

Notify only if

Insider Trading

Get notified when an Adaptive Biotechnologies Corp insider buys or sells ADPT shares.

Notify only if

News

Receive news related to Adaptive Biotechnologies Corp

Track Activities on ADPT